SeekingAlpha · Aug 6, 2026
Nephros, Inc. (NEPH) Q2 2026 Earnings Call Transcript
Nephros, Inc. (NEPH) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsRobert Banks - President, CEO & DirectorJudy Krandel - Chief...
NASDAQ · NEPH
Healthcare · Medical - Instruments & Supplies
$4.08
Down-$0.33 (-7.38%)
Updated Aug 23, 2026, 3:40 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NEPH closed at $4.08 after 20 trading sessions, up 18.95% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $4.41 | $4.42 | $3.78 | $4.08 | 100.71K |
| Aug 20, 2026 | $4.87 | $4.87 | $4.295 | $4.405 | 44.89K |
| Aug 19, 2026 | $4.60 | $4.87 | $4.60 | $4.76 | 19.62K |
| Aug 18, 2026 | $4.35 | $4.70 | $4.315 | $4.59 | 18.92K |
| Aug 17, 2026 | $4.66 | $4.66 | $4.03 | $4.32 | 81.51K |
| Aug 14, 2026 | $4.70 | $4.70 | $4.2301 | $4.625 | 10.41K |
| Aug 13, 2026 | $4.41 | $4.70 | $4.35 | $4.69 | 47.35K |
| Aug 12, 2026 | $4.41 | $4.4295 | $4.1565 | $4.36 | 14.82K |
| Aug 11, 2026 | $4.46 | $4.515 | $4.00 | $4.27 | 20.36K |
| Aug 10, 2026 | $4.41 | $4.7796 | $4.26 | $4.38 | 28.37K |
| Aug 7, 2026 | $3.80 | $4.60 | $3.6206 | $4.21 | 67.77K |
| Aug 6, 2026 | $3.495 | $3.59 | $3.495 | $3.59 | 18.37K |
| Aug 5, 2026 | $3.57 | $3.58 | $3.4932 | $3.58 | 2.22K |
| Aug 4, 2026 | $3.41 | $3.75 | $3.41 | $3.59 | 6.37K |
| Aug 3, 2026 | $3.35 | $3.625 | $3.35 | $3.51 | 58.16K |
| Jul 31, 2026 | $3.36 | $3.395 | $3.36 | $3.39 | 3.77K |
| Jul 30, 2026 | $3.41 | $3.50 | $3.28 | $3.50 | 10.43K |
| Jul 29, 2026 | $3.55 | $3.55 | $3.24 | $3.2401 | 16.88K |
| Jul 28, 2026 | $3.41 | $3.50 | $3.20 | $3.50 | 26.97K |
| Jul 27, 2026 | $3.65 | $3.65 | $3.3987 | $3.43 | 8.09K |
The latest Smart Investors Daily articles mentioning NEPH.
NEPH research
Company profile and research snapshot.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 8, 2025 | Maxim Group | Buy | — |
| Nov 12, 2024 | Benchmark | Speculative Buy | — |
| May 15, 2024 | Benchmark | Speculative Buy | — |
| Mar 8, 2024 | Benchmark | Speculative Buy | — |
| Jan 26, 2021 | B. Riley FBR | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Nephros, Inc. (NEPH) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsRobert Banks - President, CEO & DirectorJudy Krandel - Chief...
Benzinga · Aug 6, 2026
Gainers Innovate (NYSE:VATE) shares moved upwards by 36.9% to $10.15 during Thursday's after-market session. The market value of their outstanding shares is at $103.1 million. As per the news, the Q2 earnings
Benzinga · Aug 6, 2026
Nephros (NASDAQ:NEPH) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 450 percent increase over earnings of $0.02 per share from the same
SeekingAlpha · Jul 16, 2026
Nephros, Inc. (NEPH) Discusses Evolving Water Safety Strategies and Expansion Beyond Filtration July 16, 2026 12:00 PM EDTCompany ParticipantsRobert Banks -...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning NEPH.
No results
No recent SID articles mention NEPH.